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Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hy-
perlipidemic hemodialysis patients. The incidence of atherosclerosis in
hemodialysis (HD) patients is very high. Major risk factors are aging,
lipid metabolism disturbances, high blood pressure, and smoking. High
blood pressure and hypertriglyceridemia, which is atherogenic in the
presence of smoking, are encountered very often in HD patients. The
effects of eicosapentaenoic acid (EPA) on plasma lipids and blood pres-
sure were studied for the first time in HD patients by the administra-
tion of capsules containing fish oil rich in EPA, which is known to
lower serum lipid concentration and blood pressure. We treated 12
hyperlipidemic patients (3 of type ha, 3 of type JIb, and 6 of type IV;
3 males, 9 females; 31 to 70 years of age; 4 to 90 months on HD) with
24 capsules (1.6 g EPA and 1.0 g docosahexaenoic acid) per day for 13
weeks. Serum triglycerides, total cholesterol, and phospholipid de-
creased significantly after capsule administration. The ratio of EPA to
arachidonic acid in serum increased significantly. There was a small
but statistically significant decrease in platelet count. Diastolic blood
pressure decreased at the end of the experiment. These effects of fish
oil are considered favorable for the prevention of atherosclerosis and
its subsequent diseases.
Effets d'une huile de poisson riche en acide eicosapentaénoIque sur les
lipides sériques chez des malades hemodialysés hyperlipidémiques.
L'incidence de l'athérosclérose chez les malades hémodialysés (HD)
est très élevée. Les facteurs de risque majeurs d'athérosclérose sont
l'age, les perturbations du métabolisme des lipides, une pression
artérielle élevée, et le tabagisme. Une pression artérielle élevée et une
hypertriglycéridemie, laquelle est athérogéne en presence d'un taba-
gisme, sont très souvent rencontrées chez les malades HD. Les effets
de l'acide eicosapentaénoIque (EPA) sur les lipides plasmatiques et Ia
pression artérielle ont été étudiés pour la premiere fois chez des
malades HD en administrant des capsules contenant une huile de Pois-
son riche en EPA, qui est connue pour abaisser la concentration en
lipides sériques et Ia pression artérielle. Douze malades hyperlipidé-
miques (trois de type ha, 3 de type Jib, et 6 de type IV; 3 hommes, 9
femmes, 31 a 70 ans; 4 a 90 mois en HD) ont été traités avec 24 cap-
sules (1,6 g d'EPA et 1,0 g d'acide docosahexénoique) par jour pen-
dant 13 semaines. Les triglycerides, Ic cholesterol total, et les phospho-
lipides seriques ont significativement diminué apres administration des
capsules. Le rapport de l'EPA a l'acide arachidonique dans le serum
s'est élevé significativement. Ii y a eu une diminution faible mais sig-
nificative du nombre de plaquettes. La pression artérielle diastolique a
baissé a Ia fin de l'expérience. Ces effets de l'huile de poisson sont
considérés favorables pour prévenir l'athérosclérose et les maladies qui
en résultent.
contributing factor may be the lipid metabolism disturbances,
especially hypertriglyceridemia, that are often encountered in
HD patients [2—6].
There are many clinical trials to correct the risk factors as-
sociated with premature atherosclerosis in HD patients. Many
of them are directed toward correction of disturbed lipid me-
tabolism, such as antihyperlipidemic drugs [7], dietary regi-
men [8—10], and carnitine [11]. Considering the nature of ath-
erosclerosis and its subsequent progression to thrombotic dis-
eases, one should take account of several other aspects of HD
patients, in addition to lipid metabolism disorder, to prevent
those diseases.
Since Dyerberg and Bang reported the favorable effects of w-
3 polyunsaturated fatty acids (PUFA) such as eicosapentae-
noic acid (EPA, C20:5, a-3) on the prevention of atheroscle-
rosis [12], there have appeared several clinical studies report-
ing depression of platelet function/number, decreases in blood
pressure, or improvement of serum lipids or of blood rheology
resulting from the administration of fish oil or EPA concen-
trate [13—24].
In this study we administered fish oil to HD patients to take
advantage of the multifactorial effects of to-3 PUFA on risk fac-
tors for atherosclerosis,
Methods
Twelve hyperlipidemic HD patients were investigated. They
were 31 to 70 years of age (3 males and 9 females). Duration of
HD varied from 4 to 90 months (mean, 31 months) and was
mostly over 12 months. The etiologies of kidney impairment
were chronic glomerulonephritis in 4, chronic pyelonephritis in
3, and "not defined" in 5.
None of these patients were treated with antihyperlipidemic
drugs, aritihypertensive drugs, steroids, insulin, or 13-blockers.
The purpose of the study was explained to the patients, and in-
formed consent was obtained from them. They were advised
not to change their dietary habits during the study. They had
With improvements in hemodialysis (HD) techniques, the
short-term prognosis of HD patients is getting better. Accel-
erated atherosclerosis, however, is a frequent finding [1]. A
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a Figures before the ratio sign (":") are the number of carbons
incuded in a fatty acid molecule; figures after the sign are the number of
double bonds in the fatty acid. w defines the position of the first double
bond from the methyl end of the fatty acid. AA is arachidonic acid;
EPA, eicosapentaenoic acid, DHA, docosahexaenoic acid.
been dialyzed three times per week prior to the study (Mon-
day-Wednesday-Friday or Tuesday-Thursday-Saturday), and
the schedule of HD treatment was not changed throughout the
study.
Fish oil rich in w-3 PUFA was obtained by wintering crude
sardine oil and was encapsulated in gelatin coat. Each capsule
contained 400 mg of oil with 0.2% vitamin E as a preservative
and for the prevention of possible vitamin E deficiency. The
fatty acid composition is shown in Table 1. The patients were
given 24 capsules [1.6 g of EPA and 1.0 g of docosahexaenoic
acid (DHA), 19 mg of vitamin E, and about 90 calories as a
wholel per day for 13 weeks. Blood samples for the measure-
ments of serum lipid levels, blood viscosity, and plasma fatty
acid composition were obtained before and 4 and 13 weeks af-
ter the initiation of fish oil treatment. Sampling was carried out
on Monday or Tuesday between 8 and 9 A.M. just before HD
treatment and after at least 12 hours of fasting.
The fatty acid composition of the total lipid extract of plasma
was determined as previously described [251. In brief, plasma
was separated from heparinized blood. Extraction of total
lipids from plasma was carried out according to the method of
Folch, Lees, and Stanley [261. The extract was saponified and
then acidified to give free fatty acids. Those free fatty acids
were methylated by methanolic boron trifluoride and sepa-
rated by gas chromatography.
Serum cholesterol, phospholipid [27], and triglyceride were
measured enzymatically. HDL-cholesterol was measured en-
zymatically after separation of the lipoproteins by electropho-
resis. Other characteristics of the general blood chemistry and
blood count were determined every week or every other week
using standard techniques.
Heparinized blood samples, and plasma separated from it,
were used for the determination of viscosity. Measurement was
carried out at 370 C using a viscometer (Biorheolizer Model E,
Tokyo Keiki, Tokyo) at shear rates of 37.6 and 376 per second
for whole blood viscosity and 376 per second for plasma vis-
cosity [28].
Blood pressure was measured just before the first HD treat-
ment of every week. Four consecutive weekly measurements
16:0 22.7 1.3 23.0 1.5 23.0 1.5
16:1 3.5 1.3 3.7 1.1 3.8 1.0
18:0 5.0 0.8 5.0 0.7 5.3 1.1
18:1 22.6 3.3 19.1 2.3' 20.1 2.4k'
18:2 31.5 4.9 29.7 5.4° 27.3 5.3°
18:3 1.1 0.4 0.9 0.2 0.9 0.2
20:4 (AA) 3.8 1.1 3.9 0.7 3.5 0.7
20:5 (EPA) 1.2 0.7 4.4 Ø7d 5.3 0.9d'
22:6 (DHA) 1.9 0,6 2.7 0.6d 2.9 0.6da
a Results are expressed as the percentages of each fatty acid in the
total fatty acid content of plasma. Values are the means SD (N = 12).
Only fatty acids comprising more than 1.0% of total plasma fatty acids
are listed.
b P < 0.01, c P < ooo5, d P < 0.001, compared to values before
beginning of study).
P < 0.025, P < 0.005, compared to values after 4 weeks of
treatment.
were averaged and compared with the average blood pressure
during the 4 weeks prior to fish oil administration.
Data were expressed as the means SD and treated by
paired t test.
Results
The administration of fish oil capsules was tolerated well by
all patients. No side effects were observed. One patient who
had long been complaining of headaches stopped complaining
after 3 to 4 weeks of fish oil treatment. This may have been a
placebo effect. Body weight increased 0.6 kg on the average
but not significantly at the end of study.
In all patients, the ratios of EPA and DHA to total fatty ac-
ids in plasma lipids increased significantly after 4 and 13 weeks
of fish oil treatment (Table 2). This increment roughly corre-
sponds to the decrease in fatty acids of 18:1 and 18:2. The per-
centage of other fatty acids, including arachidonic acid, did not
change significantly throughout the study.
Total triglycerides, total cholesterol, and phospholipid in se-
rum decreased significantly after 4 and 13 weeks of fish oil
treatment (Fig. 1). HDL-cholesterol levels showed a small but
insignificant increase. Serum free fatty acid did not change dur-
ing the study.
Changes in blood pressure are shown in Table 3. There was
a slight but statistically significant decrease in diastolic pres-
sure after 12 weeks of fish oil treatment.
Platelet count decreased from 156 49 (x 103/mm3) to 126
41 after 13 weeks (P < 0.005).
Whole blood and plasma viscosity did not change signifi-
cantly. Also, the whole blood viscosity standardized by hema-
tocrit did not show any significant change throughout the
study.
Discussion
Premature atherosclerosis is an important risk factor in re-
nal diseases and a major factor limiting the survival of patients
on regular maintenance HD [2]. For the prevention of pre-
mature atherosclerosis, correction of lipid disturbances is con-
sidered important. Several studies have reported possible
mechanisms of the triglyceride metabolism disturbance. These
Table 1. Fatty acid composition of fish oil capsule' Table 2. Effect of fish oil capsule administration on total plasma fatty
acid composition'















*Before 4 weeks 13 weeks
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Fig. 1. Changes in serum triglycerides (open columns), total choles-
terol (horizontally hatched columns), and phospholipids (vertically
hatched columns) after fish oil administration. Values given are the
means SD (N = 12) and are compared to the values obtained before
fish oil administration. Statistical significance is denoted by asterisks:
*p < 0.025, < 0.005, ***p < 0.001.









Systolic 125 18 129 19 125 15 127 17
Diastolic 75 12 77 13 75 9 68 9b
a The averages of four consecutive measurements are shown (mean
SD, N = 12). Blood pressure "before treatment" is the average of
weeks —3 toO; at 4 weeks it is the average of weeks 2 to 5; at 8 weeks it
is the average of weeks 6 to 9; and at 12 weeks it is the average of weeks
10 to 13.
P < 0.05.
studies tend to confirm that it is principally the catabolism of
triglyceride that is disturbed [29—331.
In this study, we observed a decrease in triglycerides as a re-
suit of fish oil treatment. The ability of fish oil to lower triglyc-
erides is well known [341, but the mechanism of action of fish
oil is not clear. w-3 PUFA may change the microenvironment
(fluidity) of lipoproteins so that they may be catabolized easier
[341.
As for the cholesterol-lowering effect, the following mecha-
nisms have been proposed [341: (1) increased fecal steroid ex-
cretion, (2) change in the fatty acid composition of lipopro-
teins, and (3) changes in the rates of synthesis and/or catabo-
lism of lipoproteins.
Only a Cew clinical studies with patients using fish oil have
been reported thus far. Hay, Durber, and Saynor administered
fish oil to 13 patients with ischemic heart disease [201. They ob-
served a prolongation of platelet survival time, a fall in platelet
count, and also falls in platelet factor 4 and /3-thromboglobulin
levels in plasma. Fish oil is known to modify hemostatic func-
tions in several ways [23], in addition to its effects on plate-
lets. For example, the bleeding times of Eskimos who eat about
5 g of EPA per day are much longer than those of Danish
people [12].
In HD patients, the disturbance of platelet function is com-
plex [35]. Because they are treated with heparin continuously,
the depression of hemostatic function should be carried out
very carefully. We used a dose of 1.6 g of EPA per day, be-
cause the sum of daily EPA ingestion from meals and this dose
of EPA is roughly equal to the amount of EPA in the normal
diet of fishing people in Japan [131. Throughout the study we
did not observe any bleeding tendency in patients adminis-
tered fish oil.
Miettinen et al [361 suggested that a decrease in the 18:2
composition of fatty acid in serum phospholipids is an indepen-
dent risk factor for coronary heart disease. However, their sug-
gestion appears to be applicable only to those who do not eat
a seafood diet, because in Greenland Eskimos, in whom ath-
erosclerosis and coronary heart disease are very rare, levels of
18:2 fatty acid in serum phospholipids are less than one third
of those of Caucasian Danes [37]. Therefore, the decrease in
18:2 fatty acid in the serum of our subjects after the adminis-
tration of fish oil capsules is not considered to be a risk factor
for coronary heart disease.
We were not able to lower blood viscosity in HD patients.
In normal volunteers it was shown that blood viscosity could
be depressed by EPA-rich fish oil [19] and EPA concentrate
[23j. In HD patients, concentrations of plasma components
change significantly from one HD session to the next. This may
be the reason why we were not able to observe any significant
change in viscosity. Red blood cell deformability, which has
been shown to be decreased in HD patients [381, may have
been increased in our study, since red cell deformability has
been reported to be improved by EPA ethylester administra-
tion [231.
In experiments with healthy volunteers, blood pressure was
depressed by fish oil administration slightly but by a statisti-
cally significant amount [18, 21]. This effect of fish oil is also
important in preventing atherosclerosis.
A specific factor to HD patients that may be atherogenic is
hyperparathyroidism. After 13 weeks of fish oil administra-
tion, parathyroid hormone levels were slightly depressed al-
though not significantly (data not shown).
In conclusion, the administration of fish oil to HD patients
was carried out without any serious side effects. Some favor-
able effects were noted: decreases in triglyceride and total cho-
lesterol levels in serum and decreases in blood pressure. Fur-
ther study of fish oil treatment in HD patients seems to be jus-
tified, but any extrapolation of our observations beyond the 13-
week period of this study should be made with caution.
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